

December 9, 2020

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Regarding accusation of a suspected violation of the Antimonopoly Act

Today, our consolidated subsidiary, TOHO PHARMACEUTICAL CO., LTD. (Head Office: Tokyo; President and Representative Director: Akira Umada) and our employee were accused by the Japan Fair Trade Commission of a suspected violation of the Antimonopoly Act in connection with bidding on the supply of ethical pharmaceuticals to the Japan Community Health care Organization (JCHO).

This is a truly regrettable situation and we sincerely apologize for causing any concern to our customers, suppliers, shareholders, and other stakeholders.

TOHO HOLDINGS CO., LTD. and TOHO PHARMACEUTICAL CO., LTD. take this situation very seriously and we ask for your understanding as all executives and employees strive for more thorough adherence to compliance and to regain the trust of all the stakeholders.